Activated dendritic cell-based tumor-specific immunotherapy against high grade glioma-Phase II trial
Phase 2
- Conditions
- High-grade glioma
- Registration Number
- JPRN-UMIN000011474
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
1. Within 28 days afetr the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse-free survival time
- Secondary Outcome Measures
Name Time Method Overall survival time Antitumor effect Immunological effect